IndustryCompany release
Scienture Q3 revenue reaches $1.25M as REZENOPY naloxone nasal spray launches
🇺🇸 Scienture Holdings, Inc. (SCNX) · Thu 19 Nov 2026
The US company reports roughly 265% sequential revenue growth, led by initial wholesale sales of its naloxone nasal spray, while still posting a net loss of about $6.0m.
Scienture Holdings reported third-quarter 2026 revenue of $1.25m, around 265% higher than in the second quarter. The increase was driven mainly by initial wholesale sales of REZENOPY (naloxone hydrochloride nasal spray 10 mg), which the company launched in August 2026 and which contributed roughly $925,000.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Scienture Holdings, Inc. ↗
Article written by VigiEye from the official source (Scienture Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Brainstorm Cell proposes governance reforms to settle NurOwn derivative suits, with $725,000 in fees
🇺🇸 Brainstorm Cell Therapeutics Inc. (BCLI) · Fri 20 Nov 2026
Medicus Pharma regains Nasdaq equity compliance after equity raise and debt-for-preferred swap
🇺🇸 Medicus Pharma Ltd. (MDCX) · Thu 19 Nov 2026
Kazia files FY2026 20-F, reporting A$61.2M cash and early paxalisib breast cancer data
Kazia Therapeutics Ltd (KZIA) · Thu 19 Nov 2026
Psyence Biomedical reports $1.94M half-year loss as equity line lifts cash to $21.1M
Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026
Psyence Biomedical adds ibogaine for opioid use disorder via new Texas subsidiary
Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026
CytoSorbents reaches operating cash flow breakeven in Q3 as operating loss narrows 59%
🇺🇸 Cytosorbents Corp (CTSO) · Thu 19 Nov 2026